This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benoist, S. Articles by Nordlinger, B. Search for Related Content PubMed PubMed Citation Articles by Benoist, S. Articles by Nordlinger, B. Social Bookmarking                            What's this?

Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?

Stéphane Benoist, Antoine Brouquet, Christophe Penna, Catherine Julié, Mostafa El Hajjam, Sophie Chagnon, Emmanuel Mitry, Philippe Rougier, Bernard Nordlinger

From the Assistance Publique–Hôpitaux de Paris, Hôpital Ambroise Paré; Department of Surgery; Department of Pathology; Department of Radiology; Department of Gastroenterology and Oncology, Boulogne; and the Université Versailles Saint Quentin en Yvelines, Versailles, France.

Address reprint requests to Stéphane Benoist MD, PhD, Service de Chirurgie Générale et Digestive, Hôpital Ambroise Paré, 9, Avenue Charles de Gaulle, 92104 Boulogne Cedex, France; e-mail: stephane.benoist{at}apr.aphp.fr

PURPOSE: Most patients with colorectal liver metastases (LMs) receive systemic chemotherapy. This study aimed to determine the significance of a complete response on imaging of LMs after chemotherapy.

PATIENTS AND METHODS: Between 1998 and 2004, 586 patients were treated for colorectal LMs in one institution. Of these, 38 with the following criteria were included in the study: fewer than 10 LMs before chemotherapy; disappearance of one or several LMs on computed tomography (CT) scan and ultrasound; surgery with intraoperative ultrasound within 4 weeks of imaging; no extrahepatic disease; follow-up at least 1 year after surgery.

RESULTS: Overall, 66 LMs disappeared after chemotherapy as seen on CT scan. Persistent macroscopic disease was observed at surgery at the site of 20 of 66 LMs, despite CT scan showing a complete response. The sites of 15 initial LMs that were not visible at surgery were resected. Pathologic examination of these sites of LMs, considered in complete response, showed viable cancer cells present in 12 of 15 cases. The sites of 31 initial LMs that were not visible at surgery were left in place during surgery; after 1 year of follow-up, 23 of 31 LMs considered in complete response had recurred in situ. Overall, persistent macroscopic or microscopic residual disease or early recurrence in situ were observed in 55 (83%) of 66 LMs having a complete response on imaging.

CONCLUSION: In most patients receiving chemotherapy for colorectal LMs, a complete response on CT scan does not mean cure.

Supported by grants from the Association pour la Recherche en Oncologie Digestive (AROLD) association.

S.B. and A.B. contributed equally to this work.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Kemeny, M. Capanu, M. D'Angelica, W. Jarnagin, D. Haviland, R. Dematteo, and Y. Fong Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer Ann. Onc., July 1, 2009; 20(7): 1236 - 1241. [Abstract] [Full Text] [PDF]

				K. Okoshi, S. Nagayama, M. Furu, Y. Mori, A. Yoshizawa, J. Toguchida, and Y. Sakai A Case Report of Pathologically Complete Response of a Huge Rectal Cancer after Systemic Chemotherapy with mFOLFOX6 Jpn. J. Clin. Oncol., June 2, 2009; (2009) hyp045v1. [Abstract] [Full Text] [PDF]

				E. Van Cutsem, J. Oliveira, and On behalf of the ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv61 - iv63. [Full Text] [PDF]

				A. J. Bilchik Perioperative Carcinoembryonic Antigen Measurements to Predict Curability After Liver Resection for Colorectal Metastases--Invited Critique Arch Surg, December 1, 2008; 143(12): 1158 - 1159. [Full Text] [PDF]

				D. G. Blazer III, Y. Kishi, D. M. Maru, S. Kopetz, Y. S. Chun, M. J. Overman, D. Fogelman, C. Eng, D. Z. Chang, H. Wang, et al. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases J. Clin. Oncol., November 20, 2008; 26(33): 5344 - 5351. [Abstract] [Full Text] [PDF]

				A. J. Bilchik, G. Poston, R. Adam, and M. A. Choti Prognostic Variables for Resection of Colorectal Cancer Hepatic Metastases: An Evolving Paradigm J. Clin. Oncol., November 20, 2008; 26(33): 5320 - 5321. [Full Text] [PDF]

				G. J. Poston, J. Figueras, F. Giuliante, G. Nuzzo, A. F. Sobrero, J.-F. Gigot, B. Nordlinger, R. Adam, T. Gruenberger, M. A. Choti, et al. Urgent Need for a New Staging System in Advanced Colorectal Cancer J. Clin. Oncol., October 10, 2008; 26(29): 4828 - 4833. [Abstract] [Full Text] [PDF]

				S. R. Alberts and L. D. Wagman Chemotherapy for Colorectal Cancer Liver Metastases Oncologist, October 1, 2008; 13(10): 1063 - 1073. [Abstract] [Full Text] [PDF]

				R. Adam, D. A. Wicherts, R. J. de Haas, T. Aloia, F. Levi, B. Paule, C. Guettier, F. Kunstlinger, V. Delvart, D. Azoulay, et al. Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality? J. Clin. Oncol., April 1, 2008; 26(10): 1635 - 1641. [Abstract] [Full Text] [PDF]

				T. M. Pawlik, R. D. Schulick, and M. A. Choti Expanding Criteria for Resectability of Colorectal Liver Metastases Oncologist, January 1, 2008; 13(1): 51 - 64. [Abstract] [Full Text] [PDF]

				D. Elias, D. Goere, V. Boige, N. Kohneh-Sharhi, D. Malka, G. Tomasic, C. Dromain, and M. Ducreux Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin Ann. Surg. Oncol., November 1, 2007; 14(11): 3188 - 3194. [Abstract] [Full Text] [PDF]

				G. K. Dy, J. E. Krook, E. M. Green, D. J. Sargent, T. Delaunoit, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, et al. Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741 J. Clin. Oncol., August 10, 2007; 25(23): 3469 - 3474. [Abstract] [Full Text] [PDF]

				N. Kemeny Presurgical Chemotherapy in Patients Being Considered for Liver Resection Oncologist, July 1, 2007; 12(7): 825 - 839. [Abstract] [Full Text] [PDF]

				L Rubbia-Brandt, E Giostra, C Brezault, A. Roth, A Andres, V Audard, P Sartoretti, B Dousset, P. Majno, O Soubrane, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann. Onc., February 1, 2007; 18(2): 299 - 304. [Abstract] [Full Text] [PDF]

				L. Leichman Neoadjuvant Chemotherapy for Disseminated Colorectal Cancer: Changing the Paradigm J. Clin. Oncol., August 20, 2006; 24(24): 3817 - 3818. [Full Text] [PDF]